Generate Biomedicines director granted 29,561 options

Q: What insider transaction did Generate Biomedicines (GENB) report for Parker Paul Gray?

Generate Biomedicines reported that director Parker Paul Gray received a grant of stock options for 29,561 shares. The options were awarded on February 26, 2026 at an exercise price of $0.00 per share as part of his compensation.

Q: How many stock options did GENB director Parker Paul Gray acquire?

Parker Paul Gray acquired 29,561 stock options linked to Generate Biomedicines common shares. This grant increased his directly held derivative securities to 29,561 options following the transaction, according to the reported Form 4 insider filing data.

Q: What is the exercise price of Parker Paul Gray’s stock options at Generate Biomedicines (GENB)?

The reported stock option grant to Parker Paul Gray has an exercise price of $0.00 per share. This indicates the options were granted at no cost per share on the grant date, consistent with typical director or executive equity compensation awards.

Q: When do Parker Paul Gray’s stock options at Generate Biomedicines vest?

The stock options granted to Parker Paul Gray are scheduled to vest in full on February 19, 2027. Vesting is conditioned on his continued service with Generate Biomedicines through that date, as specified in the accompanying footnote.

Q: Is Parker Paul Gray’s stock option transaction in GENB stock a purchase or a grant?

The filing describes the transaction as a grant or award acquisition, not an open-market purchase. Code “A” on the Form 4 indicates a grant, and the transaction_direction field classifies it as an acquisition of derivative securities.

Q: How is Parker Paul Gray’s ownership classified after this GENB stock option grant?

After the grant, Parker Paul Gray holds 29,561 derivative securities (stock options) with direct ownership. The Form 4 data lists the ownership code as “D” for direct, meaning the options are held in his own name, not through an intermediary entity.

Generate Biomedicines, Inc. director Parker Paul Gray received a grant of stock options covering 29,561 shares on February 26, 2026.

Accepted by SEC EDGAR 03/02/2026 - 05:45 PM EST

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

Generate Biomedicines, Inc. director Parker Paul Gray received a grant of stock options covering 29,561 shares on February 26, 2026. The options were awarded at an exercise price of $0.00 per share as part of his compensation.

The option grant will vest in full on February 19, 2027, as long as Gray continues to serve the company through that vesting date. After this grant, he holds derivative securities representing 29,561 shares directly.

Insider Trade Summary

Grant/Award: 29,561 shares

Grant/Award 1 txn

Insider Parker Paul Gray

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	29,561	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 29,561 contracts (Direct)

Holdings Before and After: Stock Option (Right to Buy), 0 to 29,561 contracts (Direct)

Footnotes (1)

F1. The shares underlying this option shall vest in full on February 19, 2027, subject to the Reporting Person's continued service on such vesting date.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Generate Biomedicines (GENB) report for Parker Paul Gray?

Generate Biomedicines reported that director Parker Paul Gray received a grant of stock options for 29,561 shares. The options were awarded on February 26, 2026 at an exercise price of $0.00 per share as part of his compensation.

How many stock options did GENB director Parker Paul Gray acquire?

Parker Paul Gray acquired 29,561 stock options linked to Generate Biomedicines common shares. This grant increased his directly held derivative securities to 29,561 options following the transaction, according to the reported Form 4 insider filing data.

What is the exercise price of Parker Paul Gray’s stock options at Generate Biomedicines (GENB)?

The reported stock option grant to Parker Paul Gray has an exercise price of $0.00 per share. This indicates the options were granted at no cost per share on the grant date, consistent with typical director or executive equity compensation awards.

When do Parker Paul Gray’s stock options at Generate Biomedicines vest?

The stock options granted to Parker Paul Gray are scheduled to vest in full on February 19, 2027. Vesting is conditioned on his continued service with Generate Biomedicines through that date, as specified in the accompanying footnote.

Is Parker Paul Gray’s stock option transaction in GENB stock a purchase or a grant?

The filing describes the transaction as a grant or award acquisition, not an open-market purchase. Code “A” on the Form 4 indicates a grant, and the transaction_direction field classifies it as an acquisition of derivative securities.

How is Parker Paul Gray’s ownership classified after this GENB stock option grant?

After the grant, Parker Paul Gray holds 29,561 derivative securities (stock options) with direct ownership. The Form 4 data lists the ownership code as “D” for direct, meaning the options are held in his own name, not through an intermediary entity.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Parker Paul Gray

(Last)

(First)

(Middle)

GENERATE BIOMEDICINES, INC.

101 SOUTH STREET, SUITE 900

(Street)

SOMERVILLE

02143

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
Generate Biomedicines, Inc. [ GENB ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
02/26/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option (Right to Buy)	$16	02/26/2026		A		29,561		⁽¹⁾	02/25/2036	Common Stock	29,561	$0	29,561	D

Explanation of Responses:

1. The shares underlying this option shall vest in full on February 19, 2027, subject to the Reporting Person's continued service on such vesting date.

	/s/ Michael Wolf, Attorney-in-Fact	03/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR